Brazil - Drug approvals | iPharmaCenter

Brazil April 2024 Drug Approvals | ANVISA | News | Media | iPharmaCenter

16, April 2024 Rybrevant is approved in Brazil for locally advanced or metastatic non-small cell lung cancer Rybrevant (amivantamab) is...

Brazilian Health Ministry Decided to Use Unspent R$17 billion ($3.4 billion) Which was Not utilized During COVID-19 Period Approximately...

ANVISA Drug approvals | Brazil drug approvals | January 2024 | iPharmaCenter

January 09, 2024 Recombinant COVID-19 vaccine is approved by ANVISA in Brazil to prevent COVID-19 infection Designed for the immunization...

Brazil Healthcare News, Pharma News | Drug approved in Brazil | iPharmaCenter

Ondexxya is prescribed for patients undergoing treatment with FXa inhibitors such as apixaban or rivaroxaban when there is an urgent need...